Gold
bioMérieux is first and foremost a human and scientific adventure that began more than 55 years ago. Our expertise and our commitment to expand the frontiers of knowledge in biology are rooted in an entrepreneurial story that has been ongoing for more than a century. In 1897, Marcel Mérieux, who had studied under Louis Pasteur, founded his laboratory in Lyon where he developed the first anti-tetanus sera. From the very beginning, the Institut Mérieux laid the groundwork for a bio-industrial organization that would impact both vaccinology and later on the diagnosis of infectious diseases on a global scale. bioMérieux, headquartered in Marcy l'Étoile, France, was created in 1963 by Alain Mérieux. Since 2014, Alexandre Mérieux, the great-grandson of Marcel, has been at the helm of this family owned company as Chief Executive Officer. In December 2017, he was appointed Chairman and CEO by the Board of Directors. The Company specializes in providing in vitro diagnostics solutions (systems, reagents, software and services) whose primary purpose is to identify certain pathogens. Our products are mainly used in the clinical field for diagnosing infectious diseases, and in the industrial field for the detection of microorganisms in agri-food, pharmaceutical and cosmetic products. Our solutions contribute to improving patient health and ensuring consumer safety. bioMérieux today employs nearly 13,000 people. We are present in 44 countries and serve more than 160 countries with the support of a large network of distributors.
Antimicrobial stewardship is defined as a program which seeks to ensure that the right antibiotic is given to the right patient at the right time, with the right dose and the right route, causing the least harm to the patient and future patients. In realistic terms, it is a multidisciplinary approach that aims to ensure that patients benefit from the most effective antibiotic treatments, while limiting the side effects and costs of unnecessary treatments. In vitro diagnostic tests play an essential role in combatting the antimicrobial resistance threat. bioMérieux's extensive Antimicrobial Stewardship (AMS) diagnostics offer supports appropriate antibiotic use, helping to preserve their efficacy and curb antimicrobial resistance. Putting diagnostics at the heart of Antimicrobial Stewardship helps drive informed therapy decisions: from antimicrobial initiation to optimization and discontinuation.
Your lab productivity needs evolve. WASPLab® is a flexible automated specimen processing and reading solution. When empowered by bioMérieux with end-to-end microbiology expertise and support, WASPLab® offers unbeatable efficiency. Ultimate flexibility and agility fits your specialized lab needs: Just incorporate WASPLab® conveyors and modules into your existing setup and routines – and even grow over time. Workflow at the heart – never an afterthought: bioMérieux believes automation should always contribute to efficient lab operations and rapid, reliable microbiology results. Straightforward deployment: Thanks to bioMérieux’s expert support as you integrate WASPLab®, you stay focussed on your daily tasks. Make the most of WASPLab® unique algorithms: Use with our bioMerieux chromID® range for faster reading and decision. Leverage full integration with VITEK® solutions: Gain greater efficiency by calling up ID/AST information on your WASPLab® screen.